Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030)

The Report Covers Global Biologics Therapy Market Size and Trends. The Market is Segmented by Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-Based Biologics, Gene-Based Biologics, and Other Products), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Values in USD for all the Above Segments.

Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030)

Biologics Market Size

Biologics Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 412.68 Billion
Market Size (2030) USD 679.56 Billion
CAGR (2025 - 2030) 10.49 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Biologics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Biologics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Biologics Market Analysis

The Biologics Market size is estimated at USD 412.68 billion in 2025, and is expected to reach USD 679.56 billion by 2030, at a CAGR of 10.49% during the forecast period (2025-2030).

The Biopharmaceutical industry is majorly driven by growing capital investment from key players, the rise in the burden of chronic diseases, the loss of patent exclusivity of leading Biological drugs, and the increasing demand for and higher acceptability of innovative therapies.

According to the WHO report published in September 2023, non-communicable diseases (NCDs) cause 41 million deaths yearly, which is equivalent to 74% of the total death rate. Annually, 17 million individuals succumb to non-communicable diseases (NCDs) before reaching the age of 70, with a substantial 86% of these premature fatalities concentrated in low- and middle-income countries. A predominant 77% of NCD-related deaths occur within the same demographic. The primary contributors to NCD mortality are cardiovascular diseases, claiming 17.9 million lives each year, trailed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including diabetes-induced kidney disease deaths). Collectively, these four disease categories contribute to over 80% of all premature NCD deaths. Factors such as tobacco use, physical inactivity, harmful alcohol consumption, unhealthy dietary practices, and air pollution significantly elevate the risk of succumbing to NCDs. The increasing cases of chronic diseases are expected to increase the demand for biologics further in treating chronic diseases.

The Biologics market growth is fueled in part by increased investments. In October 2023, Syngene International, a subsidiary of Biocon Ltd, unveiled an annual investment plan surpassing USD 100 million, focusing primarily on advancing research, biologics, and small molecules, signaling significant commitment to the Biotechnology industry. Over the past five years, the company has committed a cumulative investment of approximately USD 54 million (INR 4,500 crores).

Furthermore, in March 2023, Teva, one of the Largest Biopharmaceutical Companies, made a substantial investment exceeding USD 1 billion in biologics in Europe. Recognizing the escalating demand for Biopharmaceuticals products, Teva has allocated funds to enhance biologics production technologies, specifically for Active Pharmaceutical Ingredients (APIs) involving cells for Biosimilars and novel biologics. Teva's robust pipeline encompasses biosimilars and novel biologic products across various therapeutic areas, and it is poised for delivery to patients in the coming years. At present, biotech products available in the market are manufactured within Teva's biologics production facilities in Ulm, Germany, and Vilnius, Lithuania, as well as through collaborations with external entities in Asia and the US, indicating its significant presence in the Global Biologics Market.

In addition, rising research and development activities in biologics support the Biologics market growth. For instance, in March 2023, Catalent, a leading Biopharmaceutical Research Company, signed a licensing agreement with Bhami Research Laboratory (BRL) based in India. This strategic collaboration grants Catalent access to BRL's advanced formulation technology. The primary objective for Catalent is to leverage this technology to facilitate the development of formulations, enabling the subcutaneous administration of high-concentration biologics. This empowers Catalent to engage in collaborative assessments with its clients, exploring the potential of BRL's formulation technology to reduce viscosity and enhance the delivery of high-concentration biologic products. BRL's technology exhibits versatility, applying various Monoclonal Antibodies and fusion proteins. Successful outcomes from this collaboration may lead to integrating these programs into Catalent's comprehensive formulation and manufacturing services on a larger scale.

Furthermore, Biologics market growth is anticipated to be driven by biologics product launches from key market players. For instance, in July 2023, Biocon Biologics officially announced the availability of HULIO (adalimumab-fkjp) injection, a Biosimilar to Humira (adalimumab), for patients in the United States. This milestone follows five years of successful experience with HULIO in Europe and another two years in Canada. The introduction of HULIO to the US market represents a significant expansion of its global presence. It offers patients in the United States access to a well-established and proven biosimilar option.

Moreover, in July 2022, Brii Biosciences Limited, in collaboration with TSB Therapeutics (Beijing) Co. Ltd, a majority-owned joint venture, officially launched the commercial availability of the amubarvimab/romlusevimab combination in China. The release of the initial commercial batch of these long-acting COVID-19 neutralizing antibodies on July 7 signified a significant achievement in advancing the commercialization of this innovative combination therapy.

Thus, the above-mentioned factors are anticipated to drive the Biologics industry's growth during the next five years. However, the stringent regulatory processes, high capital investment, and loss of patent exclusivity are likely to restrain the Biopharmaceutical industry growth.

Biologics Industry Overview

The Biologics Industry is moderately competitive and consists of several major players. Biopharmaceuticals Companies are implementing specific strategic initiatives such as mergers, new product launches, acquisitions, and partnerships that help them strengthen their market positions. These companies have made substantial capital investments in the research and development of biologics, as the cost of biologics is relatively high. Some top Biologics Companies include Amgen, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, AbbVie Inc., and F. Hoffmann-La Roche AG, which are among the Largest Biopharmaceutical Companies globally.

Biologics Market Leaders

  1. Amgen, Inc.

  2. Eli Lilly and Company

  3. GlaxoSmithKline PLC

  4. Abbvie Inc.

  5. F. Hoffmann- La Roche AG

  6. *Disclaimer: Major Players sorted in no particular order
Biologics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Biologics Market News

  • In September 2023, Biogen Inc. received approval from the US Food and Drug Administration (FDA) for TOFIDENCE (tocilizumab-bavi) intravenous formulation. TOFIDENCE marks the pioneering approval of the tocilizumab biosimilar in the United States, signaling a significant advancement in treatment options for specified medical conditions.
  • In June 2022, Aeglea BioTherapuetics announced that it had failed to secure a biologics license application (BLA) from the FDA after administrators issued a refusal to file for the company's biologic pegzilarginase.
  • In February 2022, Janssen Pharmaceutical Companies of Johnson & Johnson received the United States Food and Drug Administration (FDA) approval for CARVYKTI (ciltacabtagene autoleucel; cilia-cel). This biologic medicine treats adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Biologics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Capital Investment from Key Market Players
    • 4.2.2 Rise in the Prevalence of Chronic Diseases
    • 4.2.3 Growing Demand and Higher Acceptability for Innovative Therapies
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Process and Initial High Capital Investment
    • 4.3.2 Rising Control and Cost for Accessing Biologics
    • 4.3.3 Loss of Patent Exclusivity of the Leading Biologic Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product
    • 5.1.1 Monoclonal Antibodies
    • 5.1.2 Vaccines
    • 5.1.3 Recombinant Hormones/Proteins
    • 5.1.4 Cellular-based Biologics
    • 5.1.5 Gene-based Biologics
    • 5.1.6 Other Products
  • 5.2 By Application
    • 5.2.1 Cancer
    • 5.2.2 Infectious Diseases
    • 5.2.3 Autoimmune Diseases
    • 5.2.4 Other Applications
  • 5.3 By Source
    • 5.3.1 Microbial
    • 5.3.2 Mammalian
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck & Co.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi SA
    • 6.1.10 Bristol Myers Squibb
    • 6.1.11 AstraZeneca PLC
    • 6.1.12 Novartis AG
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Biologics Industry Segmentation

The term "biologics" refers to large, complex molecules made in living cells grown in a laboratory. Biologic medicines are often 200 to 1,000 times the size of a small molecule or chemical drug. Due to their large molecular size and fragile molecular structure, biologics are majorly delivered through parenteral routes. 

The biologics industry report is segmented by product, application, source, and geography. The product is further segmented into monoclonal antibodies, vaccines, recombinant hormones/proteins, cellular-based biologics, gene-based biologics, and other products. The application is divided into cancer, infectious, autoimmune, and other applications. The source is further bifurcated into microbial and mammalian. Geography segmented is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The biologics report also covers the estimated market size and trends for 17 countries across major global regions. The report offers the biologics market size and forecasts in value in USD for all the above-mentioned segments. 

By Product Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-based Biologics
Gene-based Biologics
Other Products
By Application Cancer
Infectious Diseases
Autoimmune Diseases
Other Applications
By Source Microbial
Mammalian
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Biologics Market Research FAQs

How big is the Biologics Market?

The Biologics Market size is expected to reach USD 412.68 billion in 2025 and grow at a CAGR of 10.49% to reach USD 679.56 billion by 2030.

What is the current Biologics Market size?

In 2025, the Biologics Market size is expected to reach USD 412.68 billion.

Who are the key players in Biologics Market?

Amgen, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Abbvie Inc. and F. Hoffmann- La Roche AG are the major companies operating in the Biologics Market.

Which is the fastest growing region in Biologics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Biologics Market?

In 2025, the North America accounts for the largest market share in Biologics Market.

What years does this Biologics Market cover, and what was the market size in 2024?

In 2024, the Biologics Market size was estimated at USD 369.39 billion. The report covers the Biologics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Biologics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Biologic Therapy Industry Report

This comprehensive report offers a deep dive into the biologics industry, providing a detailed analysis of key market drivers and market segments. Mordor Intelligence offers customization based on your specific interests, including: 1. Devices: Syringes, Pens, and Pumps 2. Product: Antisense, RNAi & Molecular Therapy 3. Application: Oncology, Immunological Disorders, Cardiovascular Disorders, and Hematological Disorders 4. Source: Microbial, Mammalian